ArticleImmunity2014
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved.
Article in Immunity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 72 citations in OpenAlex.
- Elicitation of stem-directed antibodies in rhesus macaques by a conventional hemagglutinin immunogen.bioRxiv : the preprint server for biology · 2026Article
- Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies.The Journal of experimental medicine · 2025Article
- Transient regulatory T cell manipulation is limited by anti-antibody responses in HIV-1 envelope immunized rhesus macaques.iScience · 2025Article
- Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques.Nature communications · 2024Article
- Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells.Immunity · 2024Article
- A SMART method for isolating monoclonal antibodies from individual rhesus macaque memory B cells.Journal of immunological methods · 2024Article
- Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques.Cell · 2024Article
- Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans.AIDS research and human retroviruses · 2023Article
- Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine.Science translational medicine · 2023Article
- Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies.Cell reports · 2023Article
- Article
- Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection.Science translational medicine · 2022Article
- Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates.PLoS pathogens · 2021Article
- Article
- Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth.Science (New York, N.Y.) · 2021Article
- Article
- Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s.Frontiers in immunology · 2021Article
- Antigenic variation of SARS-CoV-2 in response to immune pressure.Molecular ecology · 2020Article
- Systematic Profiling of Full-Length Ig and TCR Repertoire Diversity in Rhesus Macaque through Long Read Transcriptome Sequencing.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 11 institutions in 3 countries.
Funding
Abstract
In HIV-1, the ability to mount antibody responses to conserved, neutralizing epitopes is critical for protection. Here we have studied the light chain usage of human and rhesus macaque antibodies targeted to a dominant region of the HIV-1 envelope second variable (V2) region involving lysine (K) 169, the site of immune pressure in the RV144 vaccine efficacy trial. We found that humans and rhesus macaques used orthologous lambda variable gene segments encoding a glutamic acid-aspartic acid (ED) motif for K169 recognition. Structure determination of an unmutated ancestor antibody demonstrated that the V2 binding site was preconfigured for ED motif-mediated recognition prior to maturation. Thus, light chain usage for recognition of the site of immune pressure in the RV144 trial is highly conserved across species. These data indicate that the HIV-1 K169-recognizing ED motif has persisted over the diversification between rhesus macaques and humans, suggesting an evolutionary advantage of this antibody recognition mode.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.